non-arteritic anterior ischemic optic neuropathy
Conditions
Interventions
Sponsors
Chiba university
Nagoya city university Kobe university
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Clinically diagnosed with Non-Arteritic Anterior Ischemic Optic Neuropathy and age >20-years and <80-years. 2. Patients who have a definitive diagnosis of Non-Arteritic Anterior Ischemic Optic Neuropathy and have been older than 6 months since their estimated onset. 3. Patients with decimal visual acuity less than 0.7 above hand motion. 4. Patients who have obtained informed consent from the person's free will, after receiving sufficient explanation for participating in this clinical trial. 5. Patients who can visit hospital for 12 weeks every 2 weeks.
Exclusion criteria
Exclusion criteria: 1. Patients with ESR>20 mm/h and CRP>10 mg/L in blood tests. 2. Patients who have been confirmed with nonarteritic ischemic optic neuropathy and who have an eye disease other than ischemic optic neuropathy by contrast-enhanced MRI. 3. Patients who have a history of drug allergy to drugs (mydriatics and anesthetics eye drops) to be used during the trial period. 4. Patients with complications that have a significant affect on visual function. 5. Patients with a history of or complications of malignancy. However, patients who have a history but have not relapsed for more than 5 years can be registered. 6. Patients diagnosed and treated for dementia and mental illness. 7. Patients complicated with poor control diabetes (HbA1c>10.0%). 8. Patients with uncontrollable hypertension systolic>180 mmHg and or diastolic 110 mmHg. 9. Patients with liver / renal dysfunction that falls under any of the following at clinical screening. AST, ALT; more than 3 times the upper limit of facility standard value Serum creatinine; more than 1.5 times the upper limit of institutional standard value 10. Patients taking ethambutol hydrochloride and / or amiodarone hydrochloride. 11. Patients who were pregnant, breastfeeding, may be or planned to be pregnant during the trial period. 12. Patients participating in other clinical trials. 13. Patients under investigational responsibility shared doctors judged inappropriate for participation in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| logMAR visual acuity | — |
Countries
Japan
Contacts
Public ContactGen Miura
Chiba university Department of ophthalmology and visual science
Outcome results
None listed